We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Blood Test Diagnoses Brain Cancer in Less Than an Hour

By LabMedica International staff writers
Posted on 28 Aug 2024
Print article
Image: The biochip is used to detect biomarkers for glioblastoma, a fast-growing brain cancer (Photo courtesy of Matt Cashore/University of Notre Dame)
Image: The biochip is used to detect biomarkers for glioblastoma, a fast-growing brain cancer (Photo courtesy of Matt Cashore/University of Notre Dame)

Glioblastoma, an aggressive and currently incurable brain cancer, typically leaves the average patient with a life expectancy of 12-18 months post-diagnosis. Now, a groundbreaking device is capable of diagnosing glioblastoma in less than an hour. This device's central component is a biochip that employs electrokinetic technology to identify biomarkers, specifically active Epidermal Growth Factor Receptors (EGFRs), which are commonly overexpressed in several cancers, including glioblastoma, and found in extracellular vesicles.

Extracellular vesicles, or exosomes, are unique and considerably large nanoparticles secreted by cells. To develop the device, the research team at the University of Notre Dame (Notre Dame, IN, USA) faced a dual challenge: distinguishing active from non-active EGFRs and building a diagnostic tool that could sensitively and selectively detect active EGFRs on extracellular vesicles from blood samples. Their solution was a biochip integrating an economical electrokinetic sensor the size of a ballpoint pen ball. This setup allows antibodies on the sensor to bind multiple times to a single vesicle, greatly enhancing both the sensitivity and specificity of the diagnosis. Additionally, synthetic silica nanoparticles are used to signal the presence of active EGFRs on captured vesicles, contributing a strong negative charge that causes a voltage shift detectable when active EGFRs are present, signaling glioblastoma.

This innovative charge-sensing approach reduces the common interferences seen in other sensor technologies that rely on electrochemical reactions or fluorescence. The diagnostic system comprises three main components: an automation interface, a portable machine prototype that supplies the necessary materials for the test, and the biochip itself. Each analysis, which consumes only 100 microliters of blood and is completed in under an hour, requires a new biochip, costing less than USD 2 to produce, while the automation interface and prototype are reusable. While initially developed for glioblastoma, this technology is versatile enough for potential adaptation to other diseases by detecting various biological nanoparticles. The research team is currently investigating its application in diagnosing pancreatic cancer and other conditions such as cardiovascular disease, dementia, and epilepsy.

“Our electrokinetic sensor allows us to do things other diagnostics cannot,” said Satyajyoti Senapati, a research associate professor of chemical and biomolecular engineering at Notre Dame and co-author of the study. “We can directly load blood without any pretreatment to isolate the extracellular vesicles because our sensor is not affected by other particles or molecules. It shows low noise and makes ours more sensitive for disease detection than other technologies.”

Related Links:
University of Notre Dame

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.